Our Mission: Highlighting Innovations by showcasing breakthroughs in cancer research, including diagnostic tools, therapies, and preventive measures.

Treatment Innovations

Innovations in cancer treatment are transforming patient care by introducing more precise, effective, and less invasive therapies. Immunotherapy, including checkpoint inhibitors and CAR-T cell therapy, has revolutionized cancer care by harnessing the immune system to target and destroy cancer cells.

Target Edonc

The Targeted Pulse: Discover the FDA’s Holiday Moves For Solid Tumors, Gastric, and GEJ Cancers

The subcutaneous formulation of nivolumab (Opdivo Qvantig) received FDA approval for all previously approved adult solid tumor indications as monotherapy, maintenance therapy, or in combination with chemotherapy or cabozantinib (Cabometyx). Data from the phase 3 CheckMate-67T study (NCT04810078) provided support for this approval. In the trial, subcutaneous nivolumab was compared with its intravenous formulation.

Read More »
ASTRO

China’s National Medical Products Administration (NMPA) Approves VYLOY™ (zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

OKYO, Jan. 5, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that China’s National Medical Products Administration (NMPA) has approved VYLOY™ (zolbetuximab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive.

Read More »
KNOW RIDGE

Coffee-based therapy may treat ovarian cancer

Researchers from the University of Kentucky Markey Cancer Center have shared encouraging early results from a new clinical trial testing a unique coffee-based product as a possible maintenance therapy for ovarian cancer.

Read More »
error: Content is protected !!